Journal of Renal Nutrition
Volume 16, Issue 3 , Pages 248-252 , July 2006

Novel Dosage Forms and Regimens for Sevelamer-Based Phosphate Binders

  • Ajay Duggal, MB, ChB

      Affiliations

    • Genzyme Europe Research, Cambridge, England.
    • Corresponding Author InformationAddress reprint requests to Ajay Duggal, 310 The Science Park, Milton Road, Cambridge CB4OWG, England.
    • ,
  • Martin Hanus, BS

      Affiliations

    • Genzyme Drug Discovery and Development, Waltham, MA.
    • ,
  • Eugene Zhorov, PhD

      Affiliations

    • Genzyme Drug Discovery and Development, Waltham, MA.
    • ,
  • Rafif Dagher, BS

      Affiliations

    • Genzyme Drug Discovery and Development, Waltham, MA.
    • ,
  • Melissa A. Plone, BA

      Affiliations

    • Genzyme Drug Discovery and Development, Waltham, MA.
    • ,
  • Jeffrey Goldberg, BS

      Affiliations

    • Genzyme Drug Discovery and Development, Waltham, MA.
    • ,
  • Steven K. Burke, MD

      Affiliations

    • Genzyme Drug Discovery and Development, Waltham, MA.

References 

  1. Chertow GM , Burke SK , Lazarus JM , et al.   Poly[allylamine hydrochloride] (RenaGel) (a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure) . Am J Kidney Dis . 1997;29:66–71
  2. Goldberg DI , Dillon MA , Slatopolsky EA , et al.   Effect of RenaGel, a non-absorbed, calcium- and aluminium-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients . Nephrol Dial Transplant . 1998;13:2303–2310
  3. Chertow GM , Dillon M , Burke SK , et al.   A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients . Clin Nephrol . 1999;51:18–26
  4. Bleyer AJ , Burke SK , Dillon M , et al.   A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients . Am J Kidney Dis . 1999;33:694–701
  5. Slatopolsky EA , Burke SK , Dillon MA  The RenaGel Study Group . RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone . Kidney Int . 1999;55:299–307
  6. Chertow GM , Burke SK , Dillon MA , et al.   Long-term effects of sevelamer hydrochloride on the calcium × phosphate product and lipid profile of haemodialysis patients . Nephrol Dial Transplant . 1999;14:2907–2914
  7. Raggi P , Boulay A , Chasan-Taber S , et al.   Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? . J Am Coll Cardiol . 2002;39:695–701
  8. Chertow GM , Burke SK , Raggi P . Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients . Kidney Int . 2002;62:245–252
  9. Chertow GM , Raggi P , Chasan-Taber S , et al.   Determinants of progressive vascular calcification in haemodialysis patients . Nephrol Dial Transplant . 2004;19:1489–1496
  10. Chertow GM , Raggi P , McCarthy JT , et al.   The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients . Am J Nephrol . 2003;23:307–314
  11. Asmus HG , Braun J , Krause R , et al.   Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density . Nephrol Dial Transplant . 2005;20:1653–1661
  12. Block GA , Spiegel DM , Ehrlich J , et al.   Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis . Kidney Int . 2005;68:1815–1824
  13. Block GA , Hulbert-Shearon T , Levin N , et al.   Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients (a national study) . Am J Kidney Dis . 1998;31:607–617
  14. Young EW , Albert JM , Satayathum S , et al.   Predictors and consequences of altered mineral metabolism (the Dialysis Outcomes and Practice Patterns Study) . Kidney Int . 2005;67:1179–1187
  15. Tomasello S , Dhupar S , Sherman RA . Phosphate binders, K/DOQI Guidelines, and compliance (the unfortunate reality) . Dial Transplant . 2004;33:238–241 291
  16. Cleary DJ , Matzke GR , Alexander AC , et al.   Medication knowledge and compliance among patients receiving long-term dialysis . Am J Health Syst Pharm . 1995;52:1895–1900
  17. Claxton AJ , Cramer J , Pierce C . A systematic review of the associations between dose regimens and medication compliance . Clin Ther . 2001;23:1296–1310
  18. Plone MA , Petersen JS , Rosenbaum DP , et al.   Sevelamer, a phosphate-binding polymer, is a non-absorbed compound . Clin Pharmacokinet . 2002;41:517–523
  19. Fischer D , Cline K , Plone M , et al.   A randomized, cross-over study to compare once a day with three times per day sevelamer dosing . Nephrol Dial Transplant . 2005;20(suppl 5):v93

PII: S1051-2276(06)00087-2

doi: 10.1053/j.jrn.2006.04.006

Journal of Renal Nutrition
Volume 16, Issue 3 , Pages 248-252 , July 2006

Article Tools

* Image Usage & Resolution